Show simple item record

dc.contributor.authorHarrold, Leslie R.
dc.contributor.authorLitman, Heather J.
dc.contributor.authorConnolly, Sean E.
dc.contributor.authorKelly, Sheila
dc.contributor.authorHua, Winnie
dc.contributor.authorAlemao, Evo
dc.contributor.authorRosenblatt, Lisa
dc.contributor.authorRebello, Sabrina
dc.contributor.authorKremer, Joel M.
dc.date2022-08-11T08:09:49.000
dc.date.accessioned2022-08-23T16:44:25Z
dc.date.available2022-08-23T16:44:25Z
dc.date.issued2018-01-01
dc.date.submitted2018-03-22
dc.identifier.citation<p>J Rheumatol. 2018 Jan;45(1):32-39. doi: 10.3899/jrheum.170007. Epub 2017 Nov 1. <a href="https://doi.org/10.3899/jrheum.170007">Link to article on publisher's site</a></p>
dc.identifier.issn0315-162X (Linking)
dc.identifier.doi10.3899/jrheum.170007
dc.identifier.pmid29093151
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40497
dc.description.abstractOBJECTIVE: Assess whether baseline anticyclic citrullinated peptide antibodies (anti-CCP) status is associated with treatment response in patients with rheumatoid arthritis (RA) initiating abatacept (ABA) or a tumor necrosis factor-alpha inhibitor (TNFi). METHODS: Using the Corrona RA registry, patients were identified who initiated ABA or a TNFi (June 2004-January 2015), had a followup visit 6 months (+/- 3 mos) after initiation, and anti-CCP measured at or prior to initiation. Primary outcome was mean change in Clinical Disease Activity Index (CDAI) from initiation to 6 months. Treatment response was evaluated based on a typical patient profile (female, aged 57 yrs, body mass index of 30 kg/m(2), baseline CDAI of 20, 1 prior biologic, and no comorbidities other than RA). Secondary outcomes included remission and low disease activity. RESULTS: There were 566 ABA initiators [anti-CCP+ ( > /= 20 units/ml): n = 362; anti-CCP- ( < 20 units/ml): n = 204] and 1715 TNFi initiators (anti-CCP+: n = 1113; anti-CCP-: n = 602). Differences between treatment groups included baseline disease duration, CDAI, and prior biologic use. At 6 months, anti-CCP+ ABA initiators were associated with significantly greater CDAI response versus anti-CCP- ABA initiators; no significant difference was observed for TNFi initiators. When considering a typical RA patient profile, CDAI response was greater in anti-CCP+ versus anti-CCP- ABA initiators; anti-CCP+ versus anti-CCP- TNFi initiators were similar. Secondary outcome responses were also greater in anti-CCP+ versus anti-CCP- ABA initiators; TNFi initiators did not differ by anti-CCP status. CONCLUSION: In a US-based clinical practice setting, anti-CCP status was associated with a differential treatment response to ABA, but not TNFi.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=29093151&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.3899/jrheum.170007
dc.rights© 2018. Free online via JRheum Full Release option.
dc.subjectanti-tumor necrosis factor
dc.subjectanticyclic citrullinated antibodies
dc.subjectdisease-modifying antirheumatic drugs
dc.subjectrheumatoid arthritis
dc.subjectImmune System Diseases
dc.subjectMusculoskeletal Diseases
dc.subjectRheumatology
dc.subjectSkin and Connective Tissue Diseases
dc.subjectTherapeutics
dc.titleEffect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-alpha Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study
dc.typeJournal Article
dc.source.journaltitleThe Journal of rheumatology
dc.source.volume45
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3300
dc.identifier.contextkey11825443
html.description.abstract<p>OBJECTIVE: Assess whether baseline anticyclic citrullinated peptide antibodies (anti-CCP) status is associated with treatment response in patients with rheumatoid arthritis (RA) initiating abatacept (ABA) or a tumor necrosis factor-alpha inhibitor (TNFi).</p> <p>METHODS: Using the Corrona RA registry, patients were identified who initiated ABA or a TNFi (June 2004-January 2015), had a followup visit 6 months (+/- 3 mos) after initiation, and anti-CCP measured at or prior to initiation. Primary outcome was mean change in Clinical Disease Activity Index (CDAI) from initiation to 6 months. Treatment response was evaluated based on a typical patient profile (female, aged 57 yrs, body mass index of 30 kg/m(2), baseline CDAI of 20, 1 prior biologic, and no comorbidities other than RA). Secondary outcomes included remission and low disease activity.</p> <p>RESULTS: There were 566 ABA initiators [anti-CCP+ ( > /= 20 units/ml): n = 362; anti-CCP- ( < 20 units/ml): n = 204] and 1715 TNFi initiators (anti-CCP+: n = 1113; anti-CCP-: n = 602). Differences between treatment groups included baseline disease duration, CDAI, and prior biologic use. At 6 months, anti-CCP+ ABA initiators were associated with significantly greater CDAI response versus anti-CCP- ABA initiators; no significant difference was observed for TNFi initiators. When considering a typical RA patient profile, CDAI response was greater in anti-CCP+ versus anti-CCP- ABA initiators; anti-CCP+ versus anti-CCP- TNFi initiators were similar. Secondary outcome responses were also greater in anti-CCP+ versus anti-CCP- ABA initiators; TNFi initiators did not differ by anti-CCP status.</p> <p>CONCLUSION: In a US-based clinical practice setting, anti-CCP status was associated with a differential treatment response to ABA, but not TNFi.</p>
dc.identifier.submissionpathoapubs/3300
dc.contributor.departmentDepartment of Orthopedics and Physical Rehabilitation
dc.source.pages32-39


This item appears in the following Collection(s)

Show simple item record